Wiebicke W, Poynter A, Montgomery M, Pagtakhan R
Krankenhaus Grosshansdorf, Zentrum für Pneumologie und Thoraxchirurgie, LVA Freie.
Pneumologie. 1990 Feb;44 Suppl 1:277-8.
The main manifestation of cystic fibrosis (CF) of the lungs is an obstructive ventilation disturbance. The fact that the administration of atropine improves pulmonary function in patients with CF suggests a vagal mechanism for the development of bronchal obstruction. In a single-blind, placebo-controlled study, we investigated the effect of 250 micrograms of an inhalation solution of the anticholinergic substance ipatropium bromide (IB) on the pulmonary function of 11 patients with CF (age range: 8 to 29 years). The mean figures for the changes in FEV1.0, FEF25-75%, RV and TLC after inhalation of IB and placebo did not differ significantly. However, FEV1.0 and FEF25-75% after administration of IB increased in 4 out of 11 patients, and decreased in one. The lung volumes changed significantly in only a single case. This variable effect of inhaled IB in CF patients is in agreement with findings that have been observed for other substances with a "bronchodilatory" effect in patients with CF.
肺部囊性纤维化（CF）的主要表现是阻塞性通气障碍。给予阿托品可改善CF患者的肺功能，这一事实提示支气管阻塞的发生存在迷走神经机制。在一项单盲、安慰剂对照研究中，我们调查了250微克抗胆碱能物质异丙托溴铵（IB）吸入溶液对11例CF患者（年龄范围：8至29岁）肺功能的影响。吸入IB和安慰剂后，FEV1.0、FEF25 - 75%、RV和TLC的平均变化值无显著差异。然而，11例患者中有4例在给予IB后FEV1.0和FEF25 - 75%增加，1例下降。仅1例患者的肺容积有显著变化。吸入IB对CF患者的这种可变效应与在CF患者中观察到的其他具有“支气管扩张”作用的物质的研究结果一致。
